Vanda Pharmaceuticals | VNDA - Créances Commerciales





Créances Commerciales Changement Date
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
Agios Pharmaceuticals USD 10.58M 5.55M 2025-12
Akebia Therapeutics USD 47.03M 19.19M 2025-12
Alnylam Pharmaceuticals USD 777.57M 187.2M 2025-12
Anika Therapeutics USD 29.33M 661K 2025-12
Arrowhead Research USD 218.87M 212.05M 2025-12
AstraZeneca USD 19.05B 1.49B 2025-12
Bristol-Myers Squibb USD 14.62B 485M 2025-09
Eli Lilly USD 19.46B 2.25B 2025-09
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
Heron Therapeutics USD 89.59M 8.54M 2025-12
Insmed USD 140.86M 75.6M 2025-12
J&J USD 17.61B 235M 2025-09
Lexicon Pharmaceuticals USD 2.38M 50K 2025-12
Ligand Pharmaceuticals USD 58.1M 15.98M 2025-09
Merck USD 12.12B 596M 2025-09
Moderna USD 184M 862M 2025-12
Novartis USD 12.29B 3.3B 2025-12
Pfizer USD 18.12B 2.02B 2025-09
PTC Therapeutics USD 181.62M 21.45M 2025-12
Puma Biotechnology USD 28.1M 3.52M 2024-06
Sangamo BioSciences USD 581K 110K 2024-06
Sanofi EUR 397M 100M 2025-12
Takeda JPY 757.92B 55.68B 2025-12
Teva Pharmaceutical Industries USD 3.71B 101M 2025-12
Ultragenyx Pharmaceutical USD 112.54M 11.92M 2025-09
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12
Veracyte USD 44.66M 3.17M 2025-12